The future of epigenetic therapy in solid tumours--lessons from the past.
Citations
1,756 citations
882 citations
Cites background from "The future of epigenetic therapy in..."
...…clinical trials have been initiated to investigate the possibility of extending their utilization to solid tumors, such as ovarian and lung cancers, either alone or in combination with other drugs (Azad et al., 2013; Juergens et al., 2011; Li et al., 2014; Matei et al., 2012;Wrangle et al., 2013)....
[...]
...Over the past few years, various DNAmethyltransferase inhibitors have been developed with the goal of reactivating aberrantly silenced genes, andmany of themhave shown encouraging results in both preclinical and clinical settings, highlighting the potential of epigenetic therapy (Azad et al., 2013; Balch and Nephew, 2013; Yamazaki and Issa, 2013)....
[...]
...More recently, clinical trials have been initiated to investigate the possibility of extending their utilization to solid tumors, such as ovarian and lung cancers, either alone or in combination with other drugs (Azad et al., 2013; Juergens et al., 2011; Li et al., 2014; Matei et al., 2012;Wrangle et al., 2013)....
[...]
...…inhibitors have been developed with the goal of reactivating aberrantly silenced genes, andmany of themhave shown encouraging results in both preclinical and clinical settings, highlighting the potential of epigenetic therapy (Azad et al., 2013; Balch and Nephew, 2013; Yamazaki and Issa, 2013)....
[...]
837 citations
771 citations
Cites background from "The future of epigenetic therapy in..."
...…new possibilities in the area of epigenetic therapy—that is, where epigenetic changes are targeted for therapeutic reversal, as discussed further in Section 9 (Egger et al. 2004; Spannhoff et al. 2009; Kelly et al. 2010; Bernt et al. 2011; Daigle et al. 2011; Dawson et al. 2012; Azad et al. 2013)....
[...]
...In cancer, the epigenome is widely altered and drugs that can broadly “reprogram” such cells and blunt many tumor pathways may be the most valuable (Jones and Baylin 2007; Baylin and Jones 2011; Dawson et al. 2012; Azad et al. 2013; Ahuja et al. 2014)....
[...]
...HDACis, used alone, however, have had little success, especially in solid tumors (Azad et al. 2013; Ahuja et al. 2014)....
[...]
...…approach called “epigenetic therapy” has been developed in which drugs that can modify chromatin or DNA methylation patterns are used alone or in combination to affect therapeutic outcomes (Egger et al. 2004; Kelly et al. 2010; Dawson and Kouzarides 2012; Azad et al. 2013; Ahuja et al. 2014)....
[...]
...…action of these compounds for blocking the catalytic site of DNMTs is quite well understood and they have been used for some time to reactivate silenced genes in tissue culture or xenograft models (Santi et al. 1984; Ghoshal et al. 2005; Kelly et al. 2010; Tsai and Baylin 2011; Azad et al. 2013)....
[...]
752 citations
Cites background from "The future of epigenetic therapy in..."
...…such resistance with epigenetic therapies, such as use of small molecules that can reverse DNA methylation and histone deacetylation, have been the subjects of recent reviews, as have implications for targeting other chromatin regulatory proteins (Azad et al., 2013; Baylin and Jones, 2011)....
[...]
References
51,099 citations
28,811 citations
10,674 citations
10,046 citations
9,355 citations